Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:JAGXNASDAQ:LTRNNASDAQ:MISTNASDAQ:VYNENASDAQ:ZYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAGXJaguar Health$0.18+6.0%$0.08$0.05▼$1.22$48.92M1.3550.93 million shs69.19 million shsLTRNLantern Pharma$5.77-3.7%$6.56$2.38▼$11.99$61.97M1.41260,088 shs106,584 shsMISTMilestone Pharmaceuticals$1.63-6.9%$1.66$1.33▼$4.49$86.63M1.77322,351 shs208,611 shsVYNEVYNE Therapeutics$2.30-4.2%$2.42$1.67▼$8.73$32.43M1.23122,275 shs11,091 shsZYNEZynerba Pharmaceuticals$1.30+2.4%$1.30$0.25▼$1.40$70.12M1.32515,333 shs862,700 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAGXJaguar Health-7.52%+42.16%+137.61%+56.90%-72.92%LTRNLantern Pharma-0.17%-22.61%-39.86%+57.22%+19.80%MISTMilestone Pharmaceuticals-0.57%+4.79%+17.45%+17.45%-52.70%VYNEVYNE Therapeutics-0.83%-10.45%+25.00%+28.34%-23.33%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%+213.25%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/ALTRNLantern Pharma0.1772 of 5 stars0.02.00.00.02.50.80.6MISTMilestone Pharmaceuticals1.9961 of 5 stars3.43.00.00.02.52.50.0VYNEVYNE Therapeutics2.653 of 5 stars3.53.00.00.02.31.71.3ZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJAGXJaguar HealthN/AN/AN/AN/ALTRNLantern Pharma2.00HoldN/AN/AMISTMilestone Pharmaceuticals2.75Moderate Buy$10.75559.51% UpsideVYNEVYNE Therapeutics3.00Buy$7.38220.65% UpsideZYNEZynerba Pharmaceuticals2.00Hold$1.11-14.62% DownsideCurrent Analyst RatingsLatest VYNE, ZYNE, LTRN, JAGX, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.003/5/2024MISTMilestone PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $5.002/29/2024VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.752/26/2024MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJAGXJaguar Health$9.76M5.01N/AN/A$0.07 per share2.53LTRNLantern PharmaN/AN/AN/AN/A$3.76 per shareN/AMISTMilestone Pharmaceuticals$1M86.63N/AN/A$0.50 per share3.26VYNEVYNE Therapeutics$420K77.21N/AN/A$6.36 per share0.36ZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)LTRNLantern Pharma-$15.96M-$1.48N/AN/AN/AN/A-34.11%-32.19%5/14/2024 (Estimated)MISTMilestone Pharmaceuticals-$59.69M-$1.39N/AN/AN/AN/A-170.99%-64.45%5/9/2024 (Estimated)VYNEVYNE Therapeutics-$28.45M-$7.04N/AN/AN/A-6,710.38%-77.46%-62.93%5/9/2024 (Estimated)ZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ALatest VYNE, ZYNE, LTRN, JAGX, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023MISTMilestone Pharmaceuticals-$0.30-$0.32-$0.02-$0.32N/AN/A3/18/2024Q4 2023LTRNLantern Pharma-$0.40-$0.39+$0.01-$0.39N/AN/A2/29/2024Q4 2023VYNEVYNE Therapeutics-$0.50-$0.20+$0.30-$0.20$0.15 million$0.08 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJAGXJaguar HealthN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJAGXJaguar Health6.332.001.34LTRNLantern PharmaN/A16.1816.18MISTMilestone Pharmaceuticals2.9710.1110.11VYNEVYNE TherapeuticsN/A12.7312.73ZYNEZynerba PharmaceuticalsN/A3.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJAGXJaguar Health12.04%LTRNLantern Pharma28.62%MISTMilestone Pharmaceuticals86.18%VYNEVYNE Therapeutics83.78%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipJAGXJaguar Health0.16%LTRNLantern Pharma6.92%MISTMilestone Pharmaceuticals10.40%VYNEVYNE Therapeutics1.80%ZYNEZynerba Pharmaceuticals13.04%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableJAGXJaguar Health49276.22 million275.77 millionNo DataLTRNLantern Pharma2110.74 million10.00 millionOptionableMISTMilestone Pharmaceuticals4753.15 million47.62 millionOptionableVYNEVYNE Therapeutics1014.10 million13.85 millionNot OptionableZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionableVYNE, ZYNE, LTRN, JAGX, and MIST HeadlinesSourceHeadlineHarmony Biosciences Reports Strong Third Quarter 2023 Financial Resultsfinance.yahoo.com - October 31 at 7:57 AMWhy Shares of Harmony Bioscience Are Falling on Fridayfool.com - October 13 at 12:59 PMNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapiesmarkets.businessinsider.com - October 11 at 9:47 AMHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEfinance.yahoo.com - October 11 at 9:47 AMH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 10 at 1:59 PMAnalysts: ZYNE stock price target of $1.25 in 12 monthsknoxdaily.com - October 5 at 6:47 PMImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructionsfinance.yahoo.com - October 4 at 7:33 PMExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 2 at 3:14 PM20 Countries With Highest Rate of Epilepsyfinance.yahoo.com - September 29 at 6:24 PMZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023finance.yahoo.com - September 29 at 1:23 PMHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealbizjournals.com - September 27 at 2:42 PMZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Riseknoxdaily.com - September 25 at 8:15 PMZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwrightknoxdaily.com - September 20 at 12:12 PMNegative sentiment towards ZYNE reflected in surge in short interestknoxdaily.com - September 15 at 8:27 PMInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Incfinance.yahoo.com - September 14 at 11:23 PMZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposiumfinance.yahoo.com - September 14 at 6:23 PMZynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statementlaw.com - September 11 at 4:04 PMPositive sentiment towards ZYNE reflected in decline in short interestknoxdaily.com - September 8 at 5:19 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLRbakersfield.com - August 31 at 5:00 PMHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)msn.com - August 16 at 4:20 AMHarmony Makes Rare Disease Play with Potential $200M Zynerba Buyoutbiospace.com - August 15 at 6:19 PMZynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?dhakatribune.com - August 15 at 6:19 PMIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - August 15 at 6:19 PMZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEmarketwatch.com - August 14 at 9:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsJaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Lantern PharmaNASDAQ:LTRNLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Milestone PharmaceuticalsNASDAQ:MISTMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.VYNE TherapeuticsNASDAQ:VYNEVYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Zynerba PharmaceuticalsNASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.